ATE71627T1 - Bryostatine. - Google Patents

Bryostatine.

Info

Publication number
ATE71627T1
ATE71627T1 AT87306552T AT87306552T ATE71627T1 AT E71627 T1 ATE71627 T1 AT E71627T1 AT 87306552 T AT87306552 T AT 87306552T AT 87306552 T AT87306552 T AT 87306552T AT E71627 T1 ATE71627 T1 AT E71627T1
Authority
AT
Austria
Prior art keywords
bryostatin
bryostatins
linneaeus
bryozoan
phylum
Prior art date
Application number
AT87306552T
Other languages
English (en)
Inventor
George R Pettit
Cherry L Herald
Yoshiaki Kamano
John E Leet
Original Assignee
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State filed Critical Univ Arizona State
Application granted granted Critical
Publication of ATE71627T1 publication Critical patent/ATE71627T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Vending Machines For Individual Products (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT87306552T 1986-07-28 1987-07-24 Bryostatine. ATE71627T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/889,946 US4833257A (en) 1986-07-28 1986-07-28 Compositions of matter and methods of using same
EP87306552A EP0264173B1 (de) 1986-07-28 1987-07-24 Bryostatine

Publications (1)

Publication Number Publication Date
ATE71627T1 true ATE71627T1 (de) 1992-02-15

Family

ID=25396026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87306552T ATE71627T1 (de) 1986-07-28 1987-07-24 Bryostatine.

Country Status (8)

Country Link
US (1) US4833257A (de)
EP (1) EP0264173B1 (de)
JP (1) JP2626889B2 (de)
AT (1) ATE71627T1 (de)
CA (1) CA1305476C (de)
DE (1) DE3776063D1 (de)
ES (1) ES2038664T3 (de)
GR (1) GR3004061T3 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256646A (en) * 1990-07-27 1993-10-26 Bristol-Myers Squibb Company Antiviral antibiotic BU-4224V
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5436400A (en) * 1993-01-19 1995-07-25 Arizona Board Of Regents Isolation and structure of spongistatin 1
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5684036A (en) * 1994-02-18 1997-11-04 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US5478861A (en) * 1994-02-18 1995-12-26 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US6060505A (en) * 1996-03-20 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of treating cancer using C-26 modified bryostatin
US6624189B2 (en) 1999-11-30 2003-09-23 The Board Of Trustees Of The Leland Stanford Junior University Byrostatin analogues, synthetic methods and uses
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE60138572D1 (de) * 2000-07-31 2009-06-10 Univ Bar Ilan Methoden und pharmazeutische zusammensetzungen zur wundheilung
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7057057B2 (en) * 2002-05-22 2006-06-06 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
WO2002087423A2 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
WO2004004641A2 (en) * 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US6900339B2 (en) 2002-04-30 2005-05-31 The University Of North Carolina At Chapel Hill Bryostatin composition and bryostatin acquisition methodologies
WO2004046104A2 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
NZ545086A (en) * 2003-08-07 2011-06-30 Healor Ltd Pharmaceutical compositions and methods for accelerating wound healing
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
WO2006052916A2 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Inc. Histone deacetylase inhibitors
JP5323481B2 (ja) * 2005-07-29 2013-10-23 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 長期記憶を増強するための、ｐｋｃ賦活薬の単独またはｐｋｃ阻害剤と組み合わせての使用
CA2625674C (en) * 2005-08-29 2015-04-14 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US20080025961A1 (en) 2006-07-28 2008-01-31 Alkon Daniel L Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
EP2754448A3 (de) 2007-02-09 2014-12-24 Blanchette Rockefeller Neurosciences, Institute Therapeutische Wirkungen von Bryostatinen, Bryologen und anderen damit zusammenhängenden Substanzen auf durch Kopftraumata herbeigeführte Gedächtnisstörungen und Hirnverletzungen
US20090036514A1 (en) 2007-02-09 2009-02-05 Sun Miao-Kun Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury
CN101835486B (zh) * 2007-07-30 2012-12-12 希尔洛有限公司 用于治疗创伤的药物组合物以及相关方法
ES2601827T3 (es) * 2009-02-24 2017-02-16 Arava Bio-Tech Ltd. Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones
WO2011083482A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of psoriasis
US20120020948A1 (en) 2010-07-08 2012-01-26 Alkon Daniel L Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke
US9597312B2 (en) 2010-08-19 2017-03-21 Cognitive Research Enterprises, Inc. Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators
US10821079B2 (en) 2011-11-13 2020-11-03 Cognitive Research Enterprises, Inc. PKC activators and combinations thereof
CN109331013B (zh) * 2012-11-27 2022-02-01 阿菲欧斯公司 苔藓素组合物、其制备方法和用途
US20180030095A1 (en) 2015-02-13 2018-02-01 George Robert Pettit Silstatin compounds
EP3294290A1 (de) 2015-05-11 2018-03-21 Alkon, Daniel, L. Behandlung neurodegenerativen erkrankungen mittels pkc-aktivatoren nach bestimmung des vorhandenseins des apoe4-allels
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
JPS60174418A (ja) * 1984-02-18 1985-09-07 Ishikawajima Harima Heavy Ind Co Ltd 下水あるいはし尿汚泥等の流動層式焼却装置
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8

Also Published As

Publication number Publication date
GR3004061T3 (de) 1993-03-31
EP0264173B1 (de) 1992-01-15
ES2038664T3 (es) 1993-08-01
JPS63183585A (ja) 1988-07-28
EP0264173A3 (en) 1988-07-13
DE3776063D1 (en) 1992-02-27
EP0264173A2 (de) 1988-04-20
JP2626889B2 (ja) 1997-07-02
CA1305476C (en) 1992-07-21
US4833257A (en) 1989-05-23

Similar Documents

Publication Publication Date Title
ATE71627T1 (de) Bryostatine.
DK172089D0 (da) 1,3-dioxolanderivater samt fremgangsmaade til fremstilling deraf
DK0559019T3 (da) 14-beta-hydroxy-10-deacetyl-baccatin III og derivater deraf som antitumormidler
NO20004978D0 (no) Semi-syntetiske ecteinascidiner
FI930977A0 (fi) Taxanderivat, deras framstaellning och onkologiska anvaendning
MC1772A1 (fr) Derives de la quinoleine
ES544752A0 (es) Un procedimiento para la preparacion de carbapenems.
ES544753A0 (es) Un procedimiento para la preparacion de carbapenems.
ATE73768T1 (de) 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8inter-m-phenylene-pgi2-derivate.
WO1988003922A3 (en) Thiophenesulfonamide herbicides
FI903779A0 (fi) S-substituerade betatioacrylamider och deras anvaendning som mikrobicider.
FI934468A0 (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter
ES2079724T3 (es) Nuevos compuestos antibioticos y su produccion.
FR2597105B1 (fr) Derives antibiotiques de la famille des 20-0-acyl-19,20-enolmacrolides
FI873000A (fi) Substituoituja 1,2,3-tiadiatsoli-4-tiolaatteja
AR241135A2 (es) "derivados de n-triazinil-n-sulfamoilurea herbicidamente activos y formulacion herbicida que los contiene".
ES2039270T3 (es) Derivados de gamma-l-glutamil-4-nitroanilida y procedimiento para determinar actividad de gamma-gtp utilizandolos.
FI862861A (fi) Regelbar baeranordning.
SU1417444A1 (ru) 2,4-Дифенил-3(4-ацетокси-4-метилгексин-2-ил)-3-азабицикло [3,3,1]нонан-9-он, проявляющий противовоспалительную активность

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee